Science news and discussion on TalkFuse.
Tirzepatide may induce sleep apnoea remission in some patients
A review of clinical trial data has found that the weight loss drug tirzepatide, sold as Mounjaro, may put obstructive sleep apnoea (OSA) into remission for many patients, offering a potential new treatment alongside existing options for a condition affecting around ten million people in the UK. Researchers stressed the drug should not replace CPAP machines, particularly for severe cases, and noted uncertainty about whether the benefit persists if patients stop taking the medication, since weight regain is common after stopping GLP-1 treatment.
Scientists from the University of Pittsburgh Medical Centre analysed two trials involving 469 patients with moderate-to-severe OSA taking tirzepatide, who lost around a fifth of their body weight and experienced more than 20 fewer breathing interruptions per hour. Between 42 and 50 per cent achieved complete remission of their OSA, roughly three times the rate seen with a placebo, with researchers in the journal JAMA Otolaryngology-Head and Neck Surgery attributing the effect mainly to weight loss reducing fat around the neck and airway. Tirzepatide is approved in the US for treating OSA in obese adults but is not licensed for this purpose in Britain.
In short
- Tirzepatide (Mounjaro) put sleep apnoea into remission for up to half of patients
- Study found weight loss reduced breathing interruptions by over 20 per hour
- Drug not licensed for OSA in the UK; not a CPAP replacement
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Tirzepatide could offer some people with obesity and moderate-to-severe sleep apnoea a treatment that addresses a major underlying contributor: excess weight around the airway. The reported reductions in breathing interruptions and higher remission rates than placebo suggest it may help patients who struggle with existing options, while potentially reducing associated health burdens.
The case against
The findings do not establish that tirzepatide should replace CPAP, especially for severe sleep apnoea, and the benefits may depend on continued treatment. Weight regain after stopping the drug could bring symptoms back, while uncertainty about long-term effects, access and use in the UK supports caution before treating remission as a durable or broadly available outcome.
Explained simply
Obstructive sleep apnoea is a condition in which the airway repeatedly narrows or closes during sleep, disrupting breathing and rest. It affects around ten million people in the UK and can range from moderate to severe.
CPAP machines are a common treatment: they keep the airway open by supplying air through a mask during sleep. Tirzepatide, sold as Mounjaro, is a medicine used for weight loss; researchers think losing weight can reduce fat around the neck and airway, which may ease obstruction.
The condition matters because repeated interruptions to breathing can affect sleep and health. Tirzepatide is not licensed to treat sleep apnoea in Britain, and it is not considered a replacement for CPAP, particularly in severe cases.
Read the full article at the source →
Originally published by Daily Mail as “Yet another benefit of weight loss jabs: They combat severe snoring, study finds”.